Drug Type Small molecule drug |
Synonyms MK 4074 |
Target |
Action inhibitors |
Mechanism ACC2 inhibitors(Acetyl-CoA carboxylase 2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC33H31N3O6 |
InChIKeyWDBNGXLHMZSUEI-UHFFFAOYSA-N |
CAS Registry1039758-22-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metabolic dysfunction-associated steatotic liver disease | Phase 1 | - | 26 Oct 2011 | |
Diabetes Mellitus | Phase 1 | United States | - | |
Fatty Liver | Phase 1 | United States | - |
Phase 1 | 31 | (MK-4074) | nesgmubbml(cpqgruinet) = fucdtgzolm joigefhxoe (amumjhygxs, rkonytorof - vcyvoxuplc) View more | - | 25 Mar 2016 | ||
(Pioglitazone) | nesgmubbml(cpqgruinet) = rgmtcdrrrp joigefhxoe (amumjhygxs, cuuldhiunl - rgvsbnrshx) View more |